Healthy Returns: Why people quit weight loss and diabetes drugs within one year
A new study examines how cost, side effects and other factors influence whether people stop GLP-1s, while Noom cuts staff to focus on GLP-1 products.
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels. Eli Lilly now expects revenue to be approximately $13.
Eli Lilly expects to beat profit forecasts on obesity drug demand
The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to sharp sell-offs in its shares.
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Diabetes and Obesity Drugs Fuel Eli Lilly Profit in the Final Quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast
Lilly forecasts 2025 profit largely above estimates on weight-loss drug strength
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular diabetes and weight-loss treatments in new markets. The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug Zepbound for the second straight quarter.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss
Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.
Nature2d
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
valuepenguin25d
Costs and Insurance Coverage for Ozempic, Wegovy & Weight Loss Drugs
You could pay about $171 per month for Mounjaro if you use a discount from the drug maker, Lilly, on top of insurance benefits. Mounjaro costs ... at-home injections. If you have insurance, ...
Yahoo Finance25d
Eli Lilly was hoping weight loss drug demand would be even bigger
Most major weight-loss drugs are delivered by weekly injections, including Lilly’s Zepbound and Novo Nordisk’s (NVO) Wegovy and Ozempic. A few pills have emerged, however: Novo sells a pill ...
Reuters26d
Lilly sues two medical spas over copycat weight-loss drugs
Jan 13 (Reuters) - Eli Lilly (LLY.N), opens ... that its compounded drug, "MEGALean - Premium Tirzepatide Injections", is clinically tested to facilitate weight loss and improve blood sugar ...
Insider2d
Weight-loss pen for sale at Morrisons has helped people lose two stone - what is Mounjaro?
The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.
Yahoo Finance26d
Eli Lilly's weight loss pill could get federal approval by early next year
Most major weight-loss drugs are delivered by weekly injections, including Eli Lilly’s popular Zepbound ... How they work, what they cost, side effects, and everything to know The growing ...